Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1997 1
2002 3
2003 3
2004 2
2005 2
2006 3
2007 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A. Koutsilieris M, et al. Among authors: milathianakis c. Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. doi: 10.1517/13543784.15.7.795. Expert Opin Investig Drugs. 2006. PMID: 16787142 Review.
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. Bogdanos J, et al. Among authors: milathianakis c. Endocr Relat Cancer. 2003 Jun;10(2):279-89. doi: 10.1677/erc.0.0100279. Endocr Relat Cancer. 2003. PMID: 12790789 Review.
Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A. Koutsilieris M, et al. Among authors: milathianakis c. BJU Int. 2007 Jul;100 Suppl 2:60-2. doi: 10.1111/j.1464-410X.2007.06958.x. BJU Int. 2007. PMID: 17594363 Review. No abstract available.
[Vaginal metastases from renal cell carcinoma].
Milathianakis CN, Karamanolakis DK, Massoud WA, Roumier X, Bogdanos IM, Perrin P. Milathianakis CN, et al. Prog Urol. 2005 Apr;15(2):319-21. Prog Urol. 2005. PMID: 15999617 Review. French.
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Mitsiades CS, et al. Among authors: milathianakis c. Clin Exp Metastasis. 2004;21(6):495-505. doi: 10.1007/s10585-004-3217-0. Clin Exp Metastasis. 2004. PMID: 15679047
Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M. Lembessis P, et al. Among authors: milathianakis c. Clin Chem Lab Med. 2007;45(11):1488-94. doi: 10.1515/CCLM.2007.301. Clin Chem Lab Med. 2007. PMID: 17924845
18 results